AKBA

Akebia TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$1.35

Analysis reference price unavailable

Analysis 2026-08-09 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$0.80

Analysis reference price unavailable

Analysis 2026-08-09 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.45

Analysis reference price unavailable

Analysis 2026-08-09 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-09

AI commentary

News coverage is limited to a small number of Q2-related articles, with no verified analyst estimate revisions, target changes, or causal post-print price reaction in the packet. Social context and options data are unavailable; zero values are placeholders for unavailable inputs, not neutral evidence. Detailed earnings figures rely on stored third-party earnings context, while the SEC filing confirms the official results release [#SEC-8K-2026-08-05]. Peer evidence is not decision-grade, so conviction remains limited.

RankAlpha Sentiment Codex - 2026-08-09

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-08-05eventMixed Q2 2026 operating updateMedium impact

Akebia filed an 8-K confirming release of Q2 2026 results [#SEC-8K-2026-08-05]. Stored earnings context reports Vafseo revenue of $21.3 million, up 60% year over year, but total revenue fell to $49.1 million and the company posted an $80.9 million net loss [#PR-EARNINGS-2026-08-06].

2026-11-07catalystErixia erosion and loss overhangHigh impact

Generic competition and pricing pressure reduced Erixia revenue, while higher R&D, SG&A, and restructuring costs widened the quarterly loss [#PR-EARNINGS-2026-08-06].

2027-08-09catalystVafseo adoption and VOICE validationHigh impact

Stored earnings context reports more than 10,500 active Vafseo patients, positive VOICE stopping-criteria results, and broader prescriber diversification. Adoption remains execution-dependent because the VOICE data had not yet been presented at a medical conference or published [#PR-EARNINGS-2026-08-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-09 • Updated nightlySource: Internal modelMethodology